BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/16/2020 11:34:55 AM | Browse: 992 | Download: 2100
 |
Received |
|
2020-01-07 18:05 |
|
Peer-Review Started |
|
2020-01-07 18:05 |
|
First Decision by Editorial Office Director |
|
2020-02-19 17:25 |
|
Return for Revision |
|
2020-02-23 02:59 |
|
Revised |
|
2020-04-04 21:14 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-04-15 08:30 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-04-18 23:54 |
|
Articles in Press |
|
2020-04-18 23:54 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-06-11 01:24 |
|
Publish the Manuscript Online |
|
2020-06-16 11:34 |
| ISSN |
2150-5330 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
P2X7 receptor antagonist recovers ileum myenteric neurons after experimental ulcerative colitis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Roberta Figueiroa Souza, Mariá Munhoz Evangelinellis, Cristina Eusébio Mendes, Marta Righetti, Múcio Cevulla Silva Lourenço and Patricia Castelucci |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Foundation São Paulo Research |
2014/25927-2 |
| Foundation São Paulo Research |
2018/07862-1 |
| Coordenação de Aperfeiçoamento de Pessoal de Nível Superior |
|
| Conselho Nacional de Desenvolvimento Científico e Tecnológico |
|
|
| Corresponding Author |
Patricia Castelucci, PhD, Associate Professor, Department of Anatomy, University of São Paulo, Lineu Prestes, 2415, São Paulo 05508-900, Brazil. pcastel@usp.br |
| Key Words |
P2X7 receptor; Brilliant blue G; Myenteric plexus; Experimental ulcerative colitis; Ileum; Chemical coding |
| Core Tip |
This work aims to analyze the effects of experimental ulcerative colitis (EUC) in ileum myenteric neurons immunoreactive (ir) for P2X7 receptor, neuronal nitric oxide synthase, choline acetyltransferase, HuC/D and enteric glial cells immunoreactive for glial fibrillary acidic protein. The animals were treated with P2X7 receptor antagonist, brilliant blue G (BBG). The results showed that the numbers of neuronal nitric oxide synthase-, choline acetyltransferase-, HuC/D-ir neurons and glial fibrillary acidic protein-ir glial cells were decreased in the EUC group and recovered in the animals treated with BBG. BBG treatment demonstrated that the P2X7 receptor may be a possible therapeutic target in the treatment of the EUC. |
| Publish Date |
2020-06-16 11:34 |
| Citation |
Souza RF, Evangelinellis MM, Mendes CE, Righetti M, Lourenço MCS, Castelucci P. P2X7 receptor antagonist recovers ileum myenteric neurons after experimental ulcerative colitis. World J Gastrointest Pathophysiol 2020; 11(4): 84-103 |
| URL |
https://www.wjgnet.com/2150-5330/full/v11/i4/84.htm |
| DOI |
https://dx.doi.org/10.4291/wjgp.v11.i4.84 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
